{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T01:12:12Z","timestamp":1775265132836,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:00:00Z","timestamp":1675728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:00:00Z","timestamp":1675728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\nDilated cardiomyopathy (DCM) is the major cause of heart failure and has a poor prognosis. The accumulating evidence points to an essential role of the inflammatory component in the process of DCM. Inhibitors of sodium-glucose cotransporter 2 (SGLT2) are widely used to treat heart failure patients due to their cardiac benefits. However, their role in DCM remains unclear. We used the doxorubicin (Dox)-induced DCM model for our study. The SGLT2 inhibitor dapagliflozin (Dapa) improved cardiac function in mice treated with doxorubicin and attenuated the activation of the nucleotide-binding oligomerization domain-like receptor family protein 3 (NLRP3) inflammasome pathway and the expression of inflammatory factors. In addition, dapagliflozin suppresses NLRP3 activation by decreasing p38-dependent toll-like receptor 4 (TLR4) expression. In our study, dagliflozin improves cardiac function in DCM by inhibiting the activity of the NLRP3 inflammasome.<\/jats:p>\n              <jats:p><jats:bold>Graphical Abstract<\/jats:bold><\/jats:p>","DOI":"10.1007\/s00210-023-02409-5","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T12:59:10Z","timestamp":1675774750000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Dapagliflozin protects against dilated cardiomyopathy progression by targeting NLRP3 inflammasome activation"],"prefix":"10.1007","author":[{"given":"Jiaxin","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiamin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dejiang","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhua","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,7]]},"reference":[{"key":"2409_CR1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00395-019-0743-0","volume":"114","author":"Y Birnbaum","year":"2019","unstructured":"Birnbaum Y, Tran D, Bajaj M, Ye Y (2019) DPP-4 inhibition by linagliptin prevents cardiac dysfunction and inflammation by targeting the Nlrp3\/ASC inflammasome. Basic Res Cardiol 114:35. https:\/\/doi.org\/10.1007\/s00395-019-0743-0","journal-title":"Basic Res Cardiol"},{"key":"2409_CR2","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nri.2016.58","volume":"16","author":"P Broz","year":"2016","unstructured":"Broz P, Dixit VM (2016) Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol 16:407\u2013420. https:\/\/doi.org\/10.1038\/nri.2016.58","journal-title":"Nat Rev Immunol"},{"key":"2409_CR3","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s10787-021-00818-7","volume":"29","author":"MA El-Rous","year":"2021","unstructured":"El-Rous MA, Saber S, Raafat EM, Ahmed AAE (2021) Dapagliflozin, an SGLT2 inhibitor, ameliorates acetic acid-induced colitis in rats by targeting NFkappaB\/AMPK\/NLRP3 axis. Inflammopharmacology 29:1169\u20131185. https:\/\/doi.org\/10.1007\/s10787-021-00818-7","journal-title":"Inflammopharmacology"},{"key":"2409_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13556","author":"D Harding","year":"2022","unstructured":"Harding D, Chong MHA, Lahoti N, Bigogno CM, Prema R, Mohiddin SA, Marelli-Berg F (2022) Dilated cardiomyopathy and chronic cardiac inflammation: Pathogenesis, diagnosis and therapy. J Intern Med. https:\/\/doi.org\/10.1111\/joim.13556","journal-title":"J Intern Med"},{"key":"2409_CR5","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nrcardio.2013.105","volume":"10","author":"RE Hershberger","year":"2013","unstructured":"Hershberger RE, Hedges DJ, Morales A (2013) Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol 10:531\u2013547. https:\/\/doi.org\/10.1038\/nrcardio.2013.105","journal-title":"Nat Rev Cardiol"},{"key":"2409_CR6","doi-asserted-by":"publisher","first-page":"e22078","DOI":"10.1096\/fj.202100909RR","volume":"36","author":"Q Ke","year":"2022","unstructured":"Ke Q, Shi C, Lv Y, Wang L, Luo J, Jiang L, Yang J, Zhou Y (2022) SGLT2 inhibitor counteracts NLRP3 inflammasome via tubular metabolite itaconate in fibrosis kidney. FASEB J 36:e22078. https:\/\/doi.org\/10.1096\/fj.202100909RR","journal-title":"FASEB J"},{"key":"2409_CR7","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","volume":"11","author":"SR Kim","year":"2020","unstructured":"Kim SR, Lee SG, Kim SH, Kim JH, Choi E, Cho W, Rim JH, Hwang I, Lee CJ, Lee M, Oh CM, Jeon JY, Gee HY, Kim JH, Lee BW, Kang ES, Cha BS, Lee MS, Yu JW, Cho JW, Kim JS, Lee YH (2020) SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun 11:2127. https:\/\/doi.org\/10.1038\/s41467-020-15983-6","journal-title":"Nat Commun"},{"key":"2409_CR8","doi-asserted-by":"publisher","first-page":"109024","DOI":"10.1016\/j.intimp.2022.109024","volume":"110","author":"Q Long","year":"2022","unstructured":"Long Q, Li L, Yang H, Lu Y, Yang H, Zhu Y, Tang Y, Liu C, Yuan J (2022) SGLT2 inhibitor, canagliflozin, ameliorates cardiac inflammation in experimental autoimmune myocarditis. Int Immunopharmacol 110:109024. https:\/\/doi.org\/10.1016\/j.intimp.2022.109024","journal-title":"Int Immunopharmacol"},{"key":"2409_CR9","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1515\/cclm-2012-0600","volume":"51","author":"B Luo","year":"2013","unstructured":"Luo B, Wang F, Li B, Dong Z, Liu X, Zhang C, An F (2013) Association of nucleotide-binding oligomerization domain-like receptor 3 inflammasome and adverse clinical outcomes in patients with idiopathic dilated cardiomyopathy. Clin Chem Lab Med 51:1521\u20131528. https:\/\/doi.org\/10.1515\/cclm-2012-0600","journal-title":"Clin Chem Lab Med"},{"key":"2409_CR10","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1161\/circulationaha.106.174287","volume":"113","author":"BJ Maron","year":"2006","unstructured":"Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB (2006) Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113:1807\u20131816. https:\/\/doi.org\/10.1161\/circulationaha.106.174287","journal-title":"Circulation"},{"key":"2409_CR11","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, Burri H, Butler J, \u010celutkien\u0117 J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, KathrineSkibelund A (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599\u20133726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"key":"2409_CR12","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/ni.1960","volume":"11","author":"EA Miao","year":"2010","unstructured":"Miao EA, Leaf IA, Treuting PM, Mao DP, Dors M, Sarkar A, Warren SE, Wewers MD, Aderem A (2010) Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria. Nat Immunol 11:1136\u20131142. https:\/\/doi.org\/10.1038\/ni.1960","journal-title":"Nat Immunol"},{"key":"2409_CR13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.pharmthera.2018.01.001","volume":"186","author":"SB Ong","year":"2018","unstructured":"Ong SB, Hern\u00e1ndez-Res\u00e9ndiz S, Crespo-Avilan GE, Mukhametshina RT, Kwek XY, Cabrera-Fuentes HA, Hausenloy DJ (2018) Inflammation following acute myocardial infarction: multiple players, dynamic roles, and novel therapeutic opportunities. Pharmacol Ther 186:73\u201387. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.01.001","journal-title":"Pharmacol Ther"},{"key":"2409_CR14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41581-020-00373-4","volume":"17","author":"U Panchapakesan","year":"2021","unstructured":"Panchapakesan U, Pollock C (2021) Organ protection beyond glycaemic control with SGLT2 inhibitors. Nat Rev Nephrol 17:223\u2013224. https:\/\/doi.org\/10.1038\/s41581-020-00373-4","journal-title":"Nat Rev Nephrol"},{"key":"2409_CR15","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.1038\/emm.2013.97","volume":"45","author":"BS Park","year":"2013","unstructured":"Park BS, Lee JO (2013) Recognition of lipopolysaccharide pattern by TLR4 complexes. Exp Mol Med 45:e66. https:\/\/doi.org\/10.1038\/emm.2013.97","journal-title":"Exp Mol Med"},{"key":"2409_CR16","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1161\/01.cir.93.5.841","volume":"93","author":"P Richardson","year":"1996","unstructured":"Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O\u2019Connell J, Olsen E, Thiene G, Goodwin J, Gyarfas I, Martin I, Nordet P (1996) Report of the 1995 World Health Organization\/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 93:841\u2013842. https:\/\/doi.org\/10.1161\/01.cir.93.5.841","journal-title":"Circulation"},{"key":"2409_CR17","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/labinvest.3700031","volume":"84","author":"M Satoh","year":"2004","unstructured":"Satoh M, Nakamura M, Akatsu T, Shimoda Y, Segawa I, Hiramori K (2004) Toll-like receptor 4 is expressed with enteroviral replication in myocardium from patients with dilated cardiomyopathy. Lab Invest 84:173\u2013181. https:\/\/doi.org\/10.1038\/labinvest.3700031","journal-title":"Lab Invest"},{"key":"2409_CR18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41572-019-0084-1","volume":"5","author":"HP Schultheiss","year":"2019","unstructured":"Schultheiss HP, Fairweather D, Caforio ALP, Escher F, Hershberger RE, Lipshultz SE, Liu PP, Matsumori A, Mazzanti A, McMurray J, Priori SG (2019) Dilated Cardiomyopathy. Nat Rev Dis Primers 5:32. https:\/\/doi.org\/10.1038\/s41572-019-0084-1","journal-title":"Nat Rev Dis Primers"},{"key":"2409_CR19","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1093\/cvr\/cvab010","volume":"118","author":"M Takahashi","year":"2022","unstructured":"Takahashi M (2022) NLRP3 inflammasome as a key driver of vascular disease. Cardiovasc Res 118:372\u2013385. https:\/\/doi.org\/10.1093\/cvr\/cvab010","journal-title":"Cardiovasc Res"},{"key":"2409_CR20","doi-asserted-by":"publisher","first-page":"H460","DOI":"10.1152\/ajpheart.00056.2019","volume":"317","author":"Z TavakoliDargani","year":"2019","unstructured":"TavakoliDargani Z, Singla DK (2019) Embryonic stem cell-derived exosomes inhibit doxorubicin-induced TLR4-NLRP3-mediated cell death-pyroptosis. Am J Physiol Heart Circ Physiol 317:H460\u2013H471. https:\/\/doi.org\/10.1152\/ajpheart.00056.2019","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2409_CR21","doi-asserted-by":"publisher","first-page":"108053","DOI":"10.1016\/j.pharmthera.2021.108053","volume":"236","author":"S Toldo","year":"2022","unstructured":"Toldo S, Mezzaroma E, Buckley LF, Potere N, Di Nisio M, Biondi-Zoccai G, Van Tassell BW, Abbate A (2022) Targeting the NLRP3 inflammasome in cardiovascular diseases. Pharmacol Ther 236:108053. https:\/\/doi.org\/10.1016\/j.pharmthera.2021.108053","journal-title":"Pharmacol Ther"},{"key":"2409_CR22","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/s0140-6736(16)31713-5","volume":"390","author":"RG Weintraub","year":"2017","unstructured":"Weintraub RG, Semsarian C, Macdonald P (2017) Dilated cardiomyopathy. The Lancet 390:400\u2013414. https:\/\/doi.org\/10.1016\/s0140-6736(16)31713-5","journal-title":"The Lancet"},{"key":"2409_CR23","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1093\/cvr\/cvaa256","volume":"117","author":"C Withaar","year":"2021","unstructured":"Withaar C, Meems LMG, Markousis-Mavrogenis G, Boogerd CJ, Sillje HHW, Schouten EM, Dokter MM, Voors AA, Westenbrink BD, Lam CSP, de Boer RA (2021) The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction. Cardiovasc Res 117:2108\u20132124. https:\/\/doi.org\/10.1093\/cvr\/cvaa256","journal-title":"Cardiovasc Res"},{"key":"2409_CR24","doi-asserted-by":"publisher","first-page":"3181278","DOI":"10.1155\/2018\/3181278","volume":"2018","author":"B Wu","year":"2018","unstructured":"Wu B, Li J, Ni H, Zhuang X, Qi Z, Chen Q, Wen Z, Shi H, Luo X, Jin B (2018) TLR4 activation promotes the progression of experimental autoimmune myocarditis to dilated cardiomyopathy by inducing mitochondrial dynamic imbalance. Oxid Med Cell Longev 2018:3181278. https:\/\/doi.org\/10.1155\/2018\/3181278","journal-title":"Oxid Med Cell Longev"},{"key":"2409_CR25","doi-asserted-by":"publisher","first-page":"e2234","DOI":"10.1038\/cddis.2016.140","volume":"7","author":"Y Yang","year":"2016","unstructured":"Yang Y, Lv J, Jiang S, Ma Z, Wang D, Hu W, Deng C, Fan C, Di S, Sun Y, Yi W (2016) The emerging role of toll-like receptor 4 in myocardial inflammation. Cell Death Dis 7:e2234. https:\/\/doi.org\/10.1038\/cddis.2016.140","journal-title":"Cell Death Dis"},{"key":"2409_CR26","doi-asserted-by":"publisher","first-page":"101523","DOI":"10.1016\/j.redox.2020.101523","volume":"34","author":"C Zeng","year":"2020","unstructured":"Zeng C, Duan F, Hu J, Luo B, Huang B, Lou X, Sun X, Li H, Zhang X, Yin S, Tan H (2020) NLRP3 inflammasome-mediated pyroptosis contributes to the pathogenesis of non-ischemic dilated cardiomyopathy. Redox Biol 34:101523. https:\/\/doi.org\/10.1016\/j.redox.2020.101523","journal-title":"Redox Biol"},{"key":"2409_CR27","doi-asserted-by":"publisher","first-page":"204062232097483","DOI":"10.1177\/2040622320974833","volume":"11","author":"QQ Zhang","year":"2020","unstructured":"Zhang QQ, Li GQ, Zhong Y, Wang J, Wang AN, Zhou X, Mao XM (2020) Empagliflozin improves chronic hypercortisolism-induced abnormal myocardial structure and cardiac function in mice. Ther Adv Chronic Dis 11:2040622320974833. https:\/\/doi.org\/10.1177\/2040622320974833","journal-title":"Ther Adv Chronic Dis"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-023-02409-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-023-02409-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-023-02409-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T15:22:44Z","timestamp":1706196164000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-023-02409-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,7]]},"references-count":27,"alternative-id":["2409"],"URL":"https:\/\/doi.org\/10.1007\/s00210-023-02409-5","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,7]]},"assertion":[{"value":"15 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol with animals was approved by the Institutional Ethics Committee of Nanjing Drum Tower Hospital and followed the guidelines outlined in the Guide for the Care and Use of Laboratory Animals (8th edition) published by the National Institutes of Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and constant participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}